Ideaya Biosciences (IDYA) announced the submission of an investigational new drug application to the FDA for IDE574, a KAT6/7 dual inhibitor with high selectivity over related KAT5/8 enzymes. The company is targeting to begin a Phase 1 dose escalation trial of monotherapy IDE574 in the first quarter of 2026.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IDYA:
- Ideaya financials not impacted by GSK termination, says Mizuho
- Ideaya disclosed termination of GSK license agreement
- IDEAYA Biosciences: Strategic Positioning and Promising Oncology Assets Drive Buy Rating
- GlaxoSmithKline Ends Collaboration with IDEAYA Biosciences
- Ideaya Biosciences announces FDA clearance of IDE034 IND application